Xillix Technologies Corp.
TSX : XLX

Xillix Technologies Corp.

July 12, 2005 08:49 ET

Xillix Announces VP, Quality, Clinical & Regulatory Affairs

RICHMOND, BRITISH COLUMBIA--(CCNMatthews - July 12, 2005) - Xillix Technologies Corp. (TSX:XLX), the world leader in fluorescence endoscopy, is pleased to announce that Mr. Rob Ngungu has joined the Company as Vice President, Quality, Clinical & Regulatory Affairs. Mr. Ngungu brings 26 years experience in quality, clinical and regulatory affairs in the commercialization of Class II and III medical devices, diagnostics and biologics, including a successful track record with the U.S. Food and Drug Administration (FDA). Mr. Ngungu has a mechanical engineering background (Hackney College, London, England) as well as an Applied Medical Sciences Certificate (Redwood Health Sciences) combined with hands-on, progressive health-care industry experience with J&J Ultrasound, Mesa Laboratories, Zimmer Arthroscopy, Baxter Diagnostics, Informedics, Inamed/McGhan Medical, OraSure and NeoRx. Mr. Ngungu has relocated from Seattle, Washington to Vancouver, Canada to direct Xillix's Quality, Clinical and Regulatory Affairs team.

"We are delighted to have Rob Ngungu join Xillix's executive management team," said Cynthia Roney, Xillix President and CEO. "Rob's appointment is timely considering recent announcement of our FDA Pre-Market Approval (PMA) Supplement for the lung cancer application of Onco-LIFE™, which Rob assisted with, as well as our plans to conduct another multi-center pivotal trial with Onco-LIFE, this time for colon cancer application. We are very fortunate to have found such a high-calibre individual with the depth of experience that Rob brings to Xillix."

About Xillix

Xillix Technologies Corp. is a Canadian medical device company and the world leader in fluorescence endoscopy for improved cancer detection. Xillix's latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers. An international multicenter lung cancer clinical trial of Onco-LIFE demonstrated a 325% per-lesion improvement in the detection of early lung cancer (moderate-severe dysplasia and carcinoma in situ) and a 250% per-patient improvement compared to white-light alone.Onco-LIFE is approved for sale in the United States for the lung application and in Europe and Canada for both lung and GI applications. Onco-LIFE is compact, user-friendly and is compatible with a wide range of endoscopes and endoscopic accessories to help maximize global market acceptance.


Note: Certain of the statements contained in this press release contain forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The Company does not expect to update forward-looking statements continually as conditions change. Investors are referred to the full discussion of risk factors associated with the Company's business contained in the Company's Annual Information Form filed with securities regulatory authorities dated March 31, 2005.

Xillix is listed on the Toronto Stock Exchange under the trading symbol "XLX".

Contact Information